Smart Immune appoints key new members to its Board of Directors
16 févr. 2024 02h00 HE
|
Smart Immune
Smart Immune appoints key new members to its Board of Directors PARIS, France, 16 February 2024 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T cell...
Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise
04 déc. 2023 06h46 HE
|
Smart Immune
Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise PARIS, France, 04 December 2023 – Smart Immune, a clinical-stage...
Smart Immune to host R&D KOL webinar on thymus-empowered ProTcell platform
10 nov. 2023 05h52 HE
|
Smart Immune
Smart Immune to host R&D KOL webinar on thymus-empowered ProTcell platform Clinical-stage T-cell progenitor therapy aims to re-arm the immune system against cancer and infection New class of...
Smart Immune to Present Details of Pioneering Clinical Study at the American Society of Hematology (ASH) Annual Meeting 2023
02 nov. 2023 09h00 HE
|
Smart Immune
Smart Immune to Present Details of Pioneering Clinical Study at the American Society of Hematology (ASH) Annual Meeting 2023 PARIS, France, 02 November 2023 – Smart Immune, a clinical-stage...
Smart Immune Showcases Data and Presentations at ESGCT
12 oct. 2023 06h00 HE
|
Smart Immune
PARIS, France, 12 October 2023 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell progenitor therapy platform to fully and rapidly re-arm the...
Smart Immune Doses First Leukemia Patients with ProTcell Therapy SMART101 in ReSET-02 Phase I/II Trial
27 sept. 2023 02h00 HE
|
Smart Immune
No safety concerns in first two patients treatedDesigned to accelerate T-cell reconstitution following haploidentical Hematopoietic Stem Cell Transplantation (HSCT) with post-transplant...
Deux premiers patients atteints de leucémie ont reçu la thérapie SMART101 de Smart Immune dans le cadre de l'essai ReSET-02 de phase I/II
27 sept. 2023 02h00 HE
|
Smart Immune
Aucune toxicité observée chez les deux premiers patients traités SMART101 est conçu pour accélérer la reconstitution immunitaire après une greffe de cellules souches haplo-identique suivie d’un...
Smart Immune to present details of the phase I/II studies of new T-cell therapy SMART101 at the European Hematology Association (EHA)
11 mai 2023 11h58 HE
|
Smart Immune
Smart Immune to present details of the phase I/II studies of new T-cell therapy SMART101 at the European Hematology Association (EHA) Two poster presentations at EHA showcase ProTcell, an innovative...
Smart Immune receives $5 million investment to further its thymus-empowered ProTcell therapy platform
17 avr. 2023 01h00 HE
|
Smart Immune
Smart Immune receives $5 million investment to further its thymus-empowered ProTcell therapy platform The new funding from the Gates Foundation will advance a Phase 1/2 clinical trial of an...
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator
30 mars 2023 07h00 HE
|
Smart Immune
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator PARIS, France, 30 March, 2023 – Smart Immune SAS, a...